- Home
- LYRA vs CLDI Comparison
LYRA vs CLDI Comparison
Compare LYRA & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- CLDI
- Stock Information
- Founded
- LYRA 2005
- CLDI 2014
- Country
- LYRA United States
- CLDI United States
- Employees
- LYRA N/A
- CLDI N/A
- Industry
- LYRA Medical/Dental Instruments
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LYRA Health Care
- CLDI Health Care
- Exchange
- LYRA Nasdaq
- CLDI Nasdaq
- Market Cap
- LYRA 7.6M
- CLDI 8.7M
- IPO Year
- LYRA 2020
- CLDI N/A
- Fundamental
- Price
- LYRA $3.88
- CLDI $1.53
- Analyst Decision
- LYRA Hold
- CLDI
- Analyst Count
- LYRA 1
- CLDI 0
- Target Price
- LYRA $16.00
- CLDI N/A
- AVG Volume (30 Days)
- LYRA 30.6K
- CLDI 235.9K
- Earning Date
- LYRA 11-12-2025
- CLDI 11-13-2025
- Dividend Yield
- LYRA N/A
- CLDI N/A
- EPS Growth
- LYRA N/A
- CLDI N/A
- EPS
- LYRA N/A
- CLDI N/A
- Revenue
- LYRA $600,000.00
- CLDI N/A
- Revenue This Year
- LYRA N/A
- CLDI N/A
- Revenue Next Year
- LYRA $106.28
- CLDI N/A
- P/E Ratio
- LYRA N/A
- CLDI N/A
- Revenue Growth
- LYRA N/A
- CLDI N/A
- 52 Week Low
- LYRA $3.69
- CLDI $1.10
- 52 Week High
- LYRA $37.50
- CLDI $33.72
- Technical
- Relative Strength Index (RSI)
- LYRA 22.62
- CLDI 48.17
- Support Level
- LYRA $5.40
- CLDI $1.10
- Resistance Level
- LYRA $4.80
- CLDI $1.56
- Average True Range (ATR)
- LYRA 0.42
- CLDI 0.14
- MACD
- LYRA -0.17
- CLDI 0.01
- Stochastic Oscillator
- LYRA 7.39
- CLDI 71.42
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.